SBIR Commercialization Plan Guide: What Each Agency Wants

The commercialization plan is the #1 weak spot in rejected SBIR proposals across every agency. Strong technical approaches with generic market claims get rejected routinely. NSF scores commercialization as a primary criterion from Phase I. DoD requires a dedicated 1-page strategy. NIH weights it less in Phase I but makes it critical in Phase II. Here's what each agency actually evaluates and how to write a plan reviewers believe.

Why commercialization plans fail

The pattern is consistent across agencies and across 500+ proposals we've reviewed at Cada: founders write excellent technical sections and then phone in the commercialization plan. They describe what their technology does without explaining who would pay for it.

The three most common failures:

1. "The market is $X billion." TAM assertions without evidence. Reviewers don't care about the total market. They care about your addressable segment and your evidence that customers exist.
2. No named customers. "Healthcare providers" is not a customer. "Memorial Sloan Kettering's pathology department" is a customer. Specificity is credibility.
3. No competitive positioning. Every technology competes with something, even if it's "doing nothing." Founders who say "there's no competition" lose credibility because reviewers know better.

How each agency evaluates commercialization

The weight and format differ significantly across agencies.

Section-by-section structure

Every strong SBIR commercialization plan covers these elements, regardless of agency. The order and emphasis shift based on where you're applying.

1. The problem and who has it

Start with the customer's pain, not your solution. Name specific customer segments. Quantify the cost of the current approach (money, time, lives, operational risk). This is where you earn the right to talk about your solution.

NSF: frame as a market opportunity with societal benefit NIH: frame as an unmet clinical need affecting patient outcomes DoD: frame as a capability gap affecting mission readiness

2. Your solution and competitive advantage

One paragraph on what your technology does differently. Not a technical deep-dive (that's in the approach section) -- a commercial framing of why your approach wins in the market.

Include a competitive landscape summary. At minimum: 3-5 alternatives (including "do nothing"), what each offers, and where your approach is genuinely better. Be honest about where competitors have advantages -- reviewers respect nuance more than claims of superiority.

3. Target customers and evidence of demand

This is where most plans fail. You need:

• Named customer segments with specific characteristics (not "hospitals" but "community hospitals with 100-500 beds processing 50K+ pathology slides annually")
• Evidence of demand. Customer discovery interviews, LOIs, pilot commitments, survey data, waitlist signups. Anything tangible.
• Letters of support from potential customers or end-users. One specific letter does more work than a page of market analysis.

The letters hierarchy (strongest to weakest):

1. Potential customer who would pilot or purchase your product
2. Strategic partner for distribution or co-development
3. Domain expert or key opinion leader
4. Investor confirming commercial viability

4. Revenue model and financial projections

Keep projections grounded. Reviewers penalize projections that aren't backed by comparable products or real customer data. Use bottom-up sizing (named customers x price x close rate), not top-down TAM percentages.

Cover:

• Pricing rationale (how you arrived at the price point, comparable products)
• Revenue streams (licensing, SaaS, device sales, service contracts)
• Addressable market (SAM, not TAM -- the segment you can realistically reach)
• Near-term milestones (first revenue, first 10 customers, break-even timeline)

NSF: financial projections are expected and evaluated NIH: focus on reimbursement pathway (CPT codes, payer analysis) for diagnostics/devices DoD: focus on the government procurement pathway and dual-use commercial revenue

5. Go-to-market strategy

How you get from prototype to revenue. Cover:

• Sales channels (direct, distribution, partnerships, government contracting)
• Regulatory pathway (FDA, FCC, ITAR -- whatever applies to your technology)
• IP strategy (patents filed/pending, freedom-to-operate, licensing approach)
• Phase II/III transition plan (Phase III is when a government agency or commercial partner contracts for your product -- it can be worth more than Phase I and II combined)

At DoD specifically, explain how Phase II leads to Phase III sole-source procurement. Naming the program office or end-user command that would be your buyer signals real defense market knowledge.

Agency-specific tips

NSF

NSF scores "Commercial Impact" as one of three primary criteria (alongside Intellectual Merit and Broader Impacts). Your commercialization plan isn't an afterthought -- it's a third of your score.

• Include a dedicated commercialization plan section (not just scattered references)
• Letters of support from potential customers are expected, not optional
• If you've completed I-Corps, reference it -- it signals commercialization readiness
• Financial projections should show a path to sustainability beyond grant funding

NIH

NIH doesn't have a standalone commercialization section in Phase I proposals. Commercial potential is woven into your Specific Aims and Research Strategy. But make no mistake: reviewers consider commercial viability in their overall impact score.

• In Phase I, focus on the clinical unmet need and your path from bench to bedside
• In Phase II, the commercialization plan becomes explicit and heavily weighted
• For diagnostics and devices: include regulatory strategy (FDA pathway) and reimbursement analysis (which billing code covers your product and which payers -- Medicare, private insurance -- would pay for it)
• Clinical end-user letters carry significant weight -- a letter from a department head at a target hospital is gold
• For therapeutics: address the IND pathway and clinical trial strategy

DoD

DoD requires a 1-page Commercialization Strategy as part of the technical volume. It's evaluated alongside Technical Merit and Team Qualifications.

• Frame as dual-use: military application AND commercial market
• Name specific military end-users and their capability gaps
• Describe the Phase III transition path -- which program office would contract for production?
• Format varies by DoD component -- AFWERX uses a specific template, Navy and Army follow DSIP guidelines. Confirm the solicitation's required format before writing.
• For AFWERX specifically: commercialization matters as much as the technical approach. Lead with commercial traction.

The one thing that matters more than everything else

If you take one thing from this guide: get a letter of support from a potential customer.

Not a generic endorsement. A specific letter from someone who would use or buy your product, explaining what problem it solves for them and why they'd adopt it.

"We manage 60,000 pathology slides annually at a cost of $12/slide. A solution that achieves comparable accuracy at $3/slide would be adopted across our 14 laboratory sites within 12 months of FDA clearance." That letter tells reviewers more about your commercial viability than 10 pages of market analysis.

Reach out 3-4 weeks before the deadline. Provide a draft the customer can edit and sign. Make it easy.

For the full cross-agency proposal strategy, see how to win an SBIR grant. For agency-specific process guidance, see our NSF pitch guide or AFWERX guide.

Want help with your commercialization framing?

The difference between a funded proposal and a rejected one is often the commercialization plan -- not the science. Our Strategy Review includes a review of your commercialization framing, customer evidence, and competitive positioning specific to your target agency.